[HTML][HTML] Roles of existing drug and drug targets for COVID-19 management
AG Ayele, EF Enyew, ZD Kifle - Metabolism Open, 2021 - Elsevier
In December 2019, a highly transmissible, pneumonia epidemic caused by a novel
coronavirus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), erupted in …
coronavirus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), erupted in …
Pharmacokinetic drug-drug interactions involving antiretroviral agents: an update
X Yu, L Zhao, Z Yuan, Y Li - Current Drug Metabolism, 2023 - ingentaconnect.com
Antiretroviral therapy is the recognized treatment for human immunodeficiency virus (HIV)
infection involving several antiviral agents. Even though highly active antiretroviral therapy …
infection involving several antiviral agents. Even though highly active antiretroviral therapy …
Therapeutic Intervention of Serine Protease Inhibitors against Hepatitis C Virus
Hepatitis C virus (HCV) is a globally prevalent and hazardous disorder that is responsible for
inducing several persistent and potentially fatal liver diseases. Current treatment strategies …
inducing several persistent and potentially fatal liver diseases. Current treatment strategies …
Phage-Related Ribosomal Protease (Prp) of Staphylococcus aureus: In Vitro Michaelis–Menten Kinetics, Screening for Inhibitors, and Crystal Structure of a Covalent …
JA Hotinger, HA Pendergrass, D Peterson… - Biochemistry, 2022 - ACS Publications
Phage-related ribosomal proteases (Prps) are essential for the assembly and maturation of
the ribosome in Firmicutes, including the human pathogens Staphylococcus aureus …
the ribosome in Firmicutes, including the human pathogens Staphylococcus aureus …
The structural, dynamic, and thermodynamic basis of darunavir resistance of a heavily mutated HIV-1 protease using molecular dynamics simulation
The human immunodeficiency virus type 1 protease (HIV-1 PR) is an important enzyme in
the life cycle of the HIV virus. It cleaves inactive pre-proteins of the virus and changes them …
the life cycle of the HIV virus. It cleaves inactive pre-proteins of the virus and changes them …
In Silico Investigation of Molecular Properties and Molecular Docking of Darunavir: An Anti‐HIV Drug
S Kumar, G Tiwari, D Sharma - Macromolecular Symposia, 2024 - Wiley Online Library
A second‐generation HIV protease enzyme inhibitor, darunavir is used in combination
therapy for patients with history of prior antiretroviral treatments. It inhibits the cleavage of …
therapy for patients with history of prior antiretroviral treatments. It inhibits the cleavage of …
Identification of FDA-Approved Drugs as Modulators of Multidrug Resistance Protein 2 (MRP2/ABCC2) Expression Levels in MRP2-Overexpressing Cells: Preliminary …
Multidrug Resistance Protein 2 (MRP2) is an ATP-dependent transmembrane protein that
plays a pivotal role in the efflux of a wide variety of physiological substrates across the …
plays a pivotal role in the efflux of a wide variety of physiological substrates across the …
Effectiveness and safety of darunavir/cobicistat/emtricitabine/tenofovir alafenamide therapy in an observational Italian cohort: the DIAMANTE study
A Antinori, A Vergori, D Ripamonti, D Valenti… - Future …, 2023 - Taylor & Francis
Aim: DIAMANTE is a retrospective and prospective, non-interventional, cohort study to
describe the effectiveness of darunavir/cobicistat/emtricitabine/tenofovir alafenamide …
describe the effectiveness of darunavir/cobicistat/emtricitabine/tenofovir alafenamide …
Understanding The Mechanism of Mutant HIV-1 Protease Resistance Against Darunavir Using Molecular Dynamic Study
Y Shabanpour, E Behmard, P Abdolmaleki, AH Keihan… - 2021 - researchsquare.com
The human immunodeficiency virus type 1 protease (HIV-1 PR) is an important enzyme in
life cycle of the HIV virus. It cleaves inactive pre-proteins of the virus and changes them into …
life cycle of the HIV virus. It cleaves inactive pre-proteins of the virus and changes them into …